AstraZeneca plc Receives Average Recommendation of “Hold” from Brokerages (NYSE:AZN)
Shares of AstraZeneca plc (NYSE:AZN) have received a consensus recommendation of “Hold” from the twenty-two analysts that are currently covering the stock, Stock Ratings News reports. Four investment analysts have rated the stock with a sell recommendation, twelve have issued a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $57.00.
A number of research firms have recently commented on AZN. Analysts at Credit Suisse reiterated a “neutral” rating on shares of AstraZeneca plc in a research note on Thursday, August 14th. Separately, analysts at Barclays reiterated an “equal weight” rating on shares of AstraZeneca plc in a research note on Monday, August 4th. Finally, analysts at Berenberg Bank reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday, July 31st.
AstraZeneca plc (NYSE:AZN) traded down 0.04% during mid-day trading on Friday, hitting $73.16. 381,966 shares of the company’s stock traded hands. AstraZeneca plc has a one year low of $48.53 and a one year high of $82.68. The stock has a 50-day moving average of $72.76 and a 200-day moving average of $70.62. The company has a market cap of $92.401 billion and a price-to-earnings ratio of 45.66. AstraZeneca plc also was the target of unusually large options trading on Thursday. Stock investors acquired 20,242 call options on the company. This represents an increase of approximately 544% compared to the typical daily volume of 3,143 call options.
AstraZeneca plc (NYSE:AZN) last posted its quarterly earnings results on Thursday, July 31st. The company reported $1.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.21. The company had revenue of $6.45 billion for the quarter, compared to the consensus estimate of $6.24 billion. During the same quarter in the previous year, the company posted $1.20 earnings per share. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. Analysts expect that AstraZeneca plc will post $4.40 EPS for the current fiscal year.
The company also recently declared a semiannual dividend, which is scheduled for Monday, September 15th. Stockholders of record on Friday, August 15th will be given a dividend of $0.90 per share. This represents a yield of 2.48%. The ex-dividend date of this dividend is Wednesday, August 13th.
AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.
Receive News & Ratings for AstraZeneca plc (ADR) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc (ADR) and related companies with Analyst Ratings Network's FREE daily email newsletter.